Aspects of a Methodological Approach to Determination of Interferon Alpha Specific Activity

Specific antiviral activity is one of the key indicators characterising pharmaceutical quality and pharmacological efficacy of interferon alpha products (IFN-α). Specific activity is determined using a bioassay measuring antiviral activity in cell culture. The aim of the study was to select the most appropriate conditions for in vitro determination of IFN-α product specific activity. Materials and methods: Vero, MDBK, Hep-2, and A-549 homologous and heterologous cell cultures, as well as vesicular stomatitis Indiana virus (VSV) and murine encephalomyocarditis (EMC) virus at a dose of 100 TCD50 /0.1 mL were used for determination of specific antiviral activity. The international reference standard of recombinant interferon alpha-2b activity (Interferon alpha 2b, human, rDNA, E. coli-derived, 2nd WHO International Standard, 1999, NIBSC Code No. 95/566) and human recombinant interferon alpha 2b in the form of solution (batch No. 040214, Pharmapark LLC, Russia) were used as IFN-α samples. Results: the analysis of the obtained data helped to determine: the combinations of cell lines and the indicator virus most sensitive to IFN-α; the optimal concentration of fetal serum in the medium, and the optimal time parameters; the preferred method of reporting test results. Conclusions: the following test conditions were found to be optimal: the MDBK/VSV and Hep-2/EMC combinations proved to be the most sensitive to IFN-α; the optimal period of interferon and cell culture incubation—24 hours; the optimal concentration of fetal bovine serum in the culture medium used for diluting interferon products—2–5%. The instrumental procedure is preferred for reporting the results of interferon antiviral activity determination, because it is up-to-date, reliable, accurate and time-efficient.

1. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem. 1987;56:727–77. https://doi.org/10.1146/annurev.bi.56.070187.003455

2. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227–64. https://doi.org/10.1146/annurev.biochem.67.1.227

3. Biron CA. Interferons alpha and beta as immune regulators — a new look. Immunity. 2001;14(6):661–4. https://doi.org/10.1016/s1074-7613(01)00154-6

4. Quesada JR, Gutterman JU, Hersh EM. Treatment of hairy cell leukemia with alpha interfe rons. Cancer. 1986;57(8 Suppl):1678–80. https://doi.org/10.1002/1097-0142(19860415)57:8+%3C1678::aid-cncr2820571308%3E3.0.co;2-6

5. Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA. 1991;266(10):1375– 83. https://doi.org/10.1001/jama.266.10.1375

6. Larocque L, Bliu A, Xu Ranran, Diress A, Wang J, Lin R, et al. Bioactivity determination of native and variant forms of therapeutic interferons. J Biomed Biotechnol. 2011;2011:174615. https://doi.org/10.1155/2011/174615

7. Meager A, Gaines Das R, Zoon K, Mire-Sluis A. Establishment of new and replacement World Health Organization International Biological Standards for human interferon alpha and omega. J Immunol Methods. 2001;257(1–2):17–33. https://doi.org/10.1016/s0022-1759(01)00460-4

8. Avdeeva ZhI, Alpatova NA, Soldatov AA, Bondarev VP, Bunyatyan ND, Merkulov VA, et al. Features of preclinical studies of biotechnological medicines. Immunologiya = Immunology. 2015;36(5):306–12 (In Russ.)

9. Meager A. Assays for antiviral activity. Methods Mol Biol. 2004;249:121–34. https://doi.org/10.1385/1-59259-667-3:121

10. Alpatova NA, Avdeeva ZhI, Soldatov AA, Bondarev VP, Medunitsyn NV. Principles of assessment of biotechnological medicines specific activity. Tsitokiny i vospalenie = Cytokines and Inflammation. 2015;14(3):10–8 (In Russ.)

11. Glanz S. Biomedical statistics. Moscow: Praktika; 1998 (In Russ.)

12.